Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
Ligand Pharmaceuticals (Nasdaq: LGND) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York. CEO Todd Davis and CFO Tavo Espinoza will present on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time.
The management team is also scheduled to host one-on-one meetings with investors and attendees during the conference. Interested investors should contact their H.C. Wainwright representative to arrange these meetings.
This event provides an opportunity for Ligand to showcase its business and engage with potential investors, potentially impacting the company's stock performance and investor relations.
Ligand Pharmaceuticals (Nasdaq: LGND) ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright a New York. Il CEO Todd Davis e il CFO Tavo Espinoza presenteranno martedì 10 settembre 2024, alle 8:30 ora orientale.
Il team di gestione è anche programmato per ospitare incontri individuali con investitori e partecipanti durante la conferenza. Gli investitori interessati dovrebbero contattare il loro rappresentante H.C. Wainwright per organizzare questi incontri.
Questo evento offre a Ligand l'opportunità di presentare il proprio business e interagire con potenziali investitori, influenzando potenzialmente le performance azionarie dell'azienda e le relazioni con gli investitori.
Ligand Pharmaceuticals (Nasdaq: LGND) anunció su participación en la 26ª Conferencia Anual de Inversiones Globales de H.C. Wainwright en Nueva York. El CEO Todd Davis y el CFO Tavo Espinoza presentarán el martes 10 de septiembre de 2024, a las 8:30 a.m. hora del Este.
El equipo de gestión también está programado para llevar a cabo reuniones individuales con inversionistas y asistentes durante la conferencia. Los inversores interesados deben contactar a su representante de H.C. Wainwright para organizar estas reuniones.
Este evento ofrece a Ligand la oportunidad de mostrar su negocio y conectarse con posibles inversionistas, lo que podría influir en el rendimiento de las acciones de la empresa y en las relaciones con los inversionistas.
리간드 제약 (Nasdaq: LGND)는 뉴욕에서 열리는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. CEO 토드 데이비스와 CFO 타보 에스피노자는 2024년 9월 10일 화요일 오전 8시 30분 동부 표준시에 발표할 예정입니다.
경영진은 또한 회의 기간 동안 투자자 및 참석자와의 일대일 회의를 주최할 예정입니다. 관심 있는 투자자는 이러한 회의를 주선하기 위해 H.C. 웨인라이트 대표에게 연락해야 합니다.
이번 행사는 리간드가 자사를 소개하고 잠재 투자자와 교류할 수 있는 기회를 제공하며, 회사의 주가 성과와 투자자 관계에 영향을 미칠 수 있습니다.
Ligand Pharmaceuticals (Nasdaq: LGND) a annoncé sa participation à la 26e Conférence Annuelle d'Investissement Mondial de H.C. Wainwright à New York. Le PDG Todd Davis et le directeur financier Tavo Espinoza feront une présentation le mardi 10 septembre 2024, à 8h30, heure de l'Est.
L'équipe de direction est également prévue pour organiser des réunions en tête-à-tête avec des investisseurs et des participants durant la conférence. Les investisseurs intéressés doivent contacter leur représentant H.C. Wainwright pour organiser ces réunions.
Cette événement offre à Ligand l'occasion de présenter son activité et d'interagir avec des investisseurs potentiels, ce qui pourrait avoir un impact sur la performance des actions de l'entreprise et sur ses relations avec les investisseurs.
Ligand Pharmaceuticals (Nasdaq: LGND) gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York bekannt. CEO Todd Davis und CFO Tavo Espinoza werden am Dienstag, den 10. September 2024, um 8:30 Uhr Eastern Time präsentieren.
Das Management-Team ist ebenfalls vorgesehen, eins-zu-eins Treffen mit Investoren und Teilnehmern während der Konferenz abzuhalten. Interessierte Investoren sollten sich an ihren H.C. Wainwright-Vertreter wenden, um diese Meetings zu organisieren.
Diese Veranstaltung bietet Ligand die Möglichkeit, sein Geschäft zu präsentieren und mit potenziellen Investoren in Kontakt zu treten, was möglicherweise die Aktienentwicklung des Unternehmens und die Beziehungen zu den Investoren beeinflussen könnte.
- None.
- None.
Management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their H.C. Wainwright representative.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. For more information, please visit at www.ligand.com. Follow Ligand on X @Ligand_LGND.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240820748761/en/
Investors:
Tavo Espinoza
investors@ligand.com
(858) 550-7766
LifeSci Advisors
Bob Yedid
bob@lifesciadvisors.com
(516) 428-8577
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
Source: Ligand Pharmaceuticals Incorporated
FAQ
When is Ligand Pharmaceuticals (LGND) presenting at the H.C. Wainwright Global Investment Conference?
Who will be representing Ligand Pharmaceuticals (LGND) at the H.C. Wainwright conference?
Can investors meet with Ligand Pharmaceuticals (LGND) management at the H.C. Wainwright conference?
Where is the H.C. Wainwright Global Investment Conference featuring Ligand Pharmaceuticals (LGND) being held?
